The company’s existing chemical APIs include cephalosporin series, statin series, carbapenem series and some other others of APIs. Due to factors such as large investment, long construction period, high technical threshold and strict environmental protection requirements, the domestic antibiotic API market is relatively highly concentrated, but the industry competition is still fierce due to overcapacity.

In order to adapt to the future competition pattern, the company gradually completed the transformation and upgrading from bulk APIs to high-end characteristic APIs, from non-standard market to standardized market and from domestic market to international market in terms of product and market.